Drug Survival of Apremilast for Psoriatic Arthritis in a Real-World Setting: A Single-Center Experience

J Rheumatol. 2023 Mar;50(3):458-459. doi: 10.3899/jrheum.220333. Epub 2022 Oct 1.

Authors

Rosario Foti¹, Elisa Visalli¹, Giorgio Amato¹, Ylenia Dal Bosco¹, Roberta Foti¹, Giacomo Baccano²

Affiliations

¹ Division of Rheumatology, A.O.U. "Policlinico San Marco", 95123 Catania, Italy.
² Division of Rheumatology, A.O.U. "Policlinico San Marco", 95123 Catania, Italy. gbaccano@gmail.com.

PMID: 36182113
DOI: 10.3899/jrheum.220333

No abstract available

Publication types

Letter

MeSH terms

Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
Arthritis, Psoriatic* / drug therapy
Humans
Psoriasis* / drug therapy
Thalidomide / therapeutic use

Substances

apremilast
Thalidomide
Anti-Inflammatory Agents, Non-Steroidal